New players in haemostasis and thrombosis

Thrombosis and Haemostasis

Volumn 111, Issue 4, 2014, Pages 570-574

  Geddings, Julia E ^a   Mackman, Nigel ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Arterial thrombosis; Coagulation factors; Deep vein thrombosis; Microparticles; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTISENSE OLIGONUCLEOTIDE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 12; DNA; HEPARIN; HISTONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; POLYAMIDOAMINE; POLYPHOSPHATE; RNA; THROMBOPLASTIN;

ANTISENSE THERAPY; APOPTOSIS; ARTICLE; HEMOSTASIS; HUMAN; MEMBRANE VESICLE; NEUTROPHIL; NEUTROPHIL EXTRACELLULAR TRAP; NONHUMAN; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOSIS; VEIN THROMBOSIS; ANIMAL; ANIMAL MODEL; BLOOD; BLOOD CLOTTING; DRUG DEVELOPMENT; MEMBRANE MICROPARTICLE; METABOLISM; MOUSE; PHYSIOLOGY;

ANIMALS; ANTICOAGULANTS; APOPTOSIS; BLOOD COAGULATION; CELL-DERIVED MICROPARTICLES; DRUG DISCOVERY; FACTOR XII; HEMOSTASIS; HUMANS; MICE; MODELS, ANIMAL; NEUTROPHILS; THROMBOPLASTIN; THROMBOSIS;

EID: 84897473752     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-10-0812     Document Type: Article

References (73)

1. Butenas S, Orfeo T, Mann KG. Tissue factor in coagulation: Which? Where? When? Arterioscler Thromb Vasc Biol 2009; 29: 1989-1996.
2. Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 2507-2513.
3. Muller F, Gailani D, Renne T. Factor XI and XII as antithrombotic targets. Current opinion in hematology 2011; 18: 349-355.
4. Konings J, Govers-Riemslag JW, Philippou H, et al. Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood 2011; 118: 3942-3951.
5. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-281.
6. Kannemeier C, Shibamiya A, Nakazawa F, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA 2007; 104: 6388-6393.
7. Muller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143-1156.
8. Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol 2012; 32: 1777-1783.
9. Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with haemostasis. J Exp Med 2006; 203: 513-518.
10. Xu Y, Cai TQ, Castriota G, et al. Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit. Thromb Haemost 2014; 111: 694-704.
11. Hagedorn I, Schmidbauer S, Pleines I, et al. Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 2010; 121: 1510-1517.
12. Yamashita A, Nishihira K, Kitazawa T, et al. Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery. J Thromb Haemost 2006; 4: 1496-1501.
13. Schumacher WA, Seiler SE, Steinbacher TE, et al. Antithrombotic and haemostatic effects of a small molecule factor XIa inhibitor in rats. Eur J Pharmacol 2007; 570: 167-174.
14. Tucker EI, Marzec UM, White TC, et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood 2009; 113: 936-944.
15. Crosby JR, Marzec U, Revenko AS, et al. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol 2013; 33: 1670-1678.
16. Leung PY, Hurst S, Berny-Lang MA, et al. Inhibition of Factor XII-Mediated Activation of Factor XI Provides Protection Against Experimental Acute Ischemic Stroke in Mice. Translat Stroke Res 2012; 3: 381-389.
17. Lowenberg EC, Meijers JC, Monia BP, et al. Coagulation factor XI as a novel target for antithrombotic treatment. J Thromb Haemost 2010; 8: 2349-2357.
18. Zhang H, Lowenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010; 116: 4684-4692.
19. Morrissey JH, Choi SH, Smith SA. Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. Blood 2012; 119: 5972-5979.
20. Smith SA, Mutch NJ, Baskar D, et al. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 2006; 103: 903-908.
21. Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. Blood 2008; 112: 2810-2816.
22. Smith SA, Choi SH, Davis-Harrison R, et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood 2010; 116: 4353-4359.
23. Smith SA, Morrissey JH. Polyphosphate as a general procoagulant agent. J Thromb Haemost 2008; 6: 1750-1756.
24. Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 2011; 118: 6963-6970.
25. Faxalv L, Boknas N, Strom JO, et al. Putting polyphosphates to the test: evidence against platelet-induced activation of factor XII. Blood 2013; 29: 29.
26. Nickel KF, Spronk HM, Mutch NJ, et al. Time-dependent degradation and tissue factor addition mask the ability of platelet polyphosphates in activating factor XII-mediated coagulation. Blood 2013; 122: 3847-3849.
27. Morrissey JH, S.A. S. Comment on Fzxalv et al. "Putting polyphosphates to the test: evidence against platelet-induced activation of factor XII". Blood 2013; e-Letter online, August 26, 2013.
28. Ghosh S, Shukla D, Suman K, et al. Inositol hexakisphosphate kinase 1 maintains haemostasis in mice by regulating platelet polyphosphate levels. Blood 2013; 122: 1478-1486.
29. Jain S, Pitoc GA, Holl EK, et al. Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proc Natl Acad Sci USA 2012; 109: 12938-12943.
30. Smith SA, Choi SH, Collins JN, et al. Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation. Blood 2012; 120: 5103-5110.
31. Gyorgy B, Szabo TG, Pasztoi M, et al. Membrane vesicles, current state-of-theart: emerging role of extracellular vesicles. Cell Mol Life Sci 2011; 68: 2667-2688.
32. D'Souza-Schorey C, Clancy JW. Tumour-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev 2012; 26: 1287-1299.
33. Owens AP, 3rd, Mackman N. Microparticles in haemostasis and thrombosis. Circ Res 2011; 108: 1284-1297.
34. Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13: 269-288.
35. Burnier L, Fontana P, Kwak BR, et al. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009; 101: 439-451.
36. Key NS, Mackman N. Tissue factor and its measurement in whole blood, plasma, and microparticles. Semin Thromb Haemost 2010; 36: 865-875.
37. Ramacciotti E, Hawley AE, Wrobleski SK, et al. Proteomics of microparticles after deep venous thrombosis. Thromb Res 2010; 125: e269-274.
38. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in haemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 1687-1693.
39. Mackman N. New insights into the mechanisms of venous thrombosis. J Clin Invest 2012; 122: 2331-2336.
40. Aleman MM, Gardiner C, Harrison P, et al. Differential contributions of monocyte-and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. J Thromb Haemost 2011; 9: 2251-2261.
41. Owens AP, 3rd, Mackman N. Tissue factor and thrombosis: The clot starts here. Thromb Haemost 2010; 104: 432-439.
42. Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res 2010; 107: 1047-1057.
43. Morrissey JH, Tajkhorshid E, Rienstra CM. Nanoscale studies of protein-membrane interactions in blood clotting. J Thromb Haemost 2011; 9 (Suppl 1): 162-167.
44. Hrachovinova I, Cambien B, Hafezi-Moghadam A, et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct haemostasis in a mouse model of haemophilia A. Nat Med 2003; 9: 1020-1025.
45. Jy W, Johansen ME, Bidot Jr C, et al. Red cell-derived microparticles (RMP) as haemostatic agent. Thromb Haemost 2013; 110: 751-760.
46. Berckmans RJ, Nieuwland R, Boing AN, et al. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 85: 639-646.
47. Biro E, Sturk-Maquelin KN, Vogel GM, et al. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost 2003; 1: 2561-2568.
48. Thomas GM, Panicot-Dubois L, Lacroix R, et al. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 2009; 206: 1913-1927.
49. Wang JG, Geddings JE, Aleman MM, et al. Tumour-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood 2012; 119: 5543-5552.
50. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-1861.
51. Pai M, Evans NS, Shah SJ, et al. Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. Thromb Res 2011; 128: 422-430.
52. Owens AP, 3rd, Passam FH, Antoniak S, et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest 2012; 122: 558-568.
53. Geddings JE, Mackman N. Tumour-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood 2013; 122: 1873-1880.
54. Myers DD, Jr., Rectenwald JE, Bedard PW, et al. Decreased venous thrombosis with an oral inhibitor of P selectin. J Vasc Surg 2005; 42: 329-336.
55. Meier TR, Myers DD, Jr., Wrobleski SK, et al. Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation. Thromb Haemost 2008; 99: 343-351.
56. Ramacciotti E, Myers DD, Jr., Wrobleski SK, et al. P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis. Thromb Res 2010; 125: e138-142.
57. Fuchs TA, Abed U, Goosmann C, et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007; 176: 231-241.
58. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532-1535.
59. Yipp BG, Kubes P. NETosis: how vital is it? Blood 2013; 5: 5.
60. Pilsczek FH, Salina D, Poon KK, et al. A novel mechanism of rapid nuclear neutrophil extracellular trap formation in response to Staphylococcus aureus. J Immunol 2010; 185: 7413-7425.
61. Yipp BG, Petri B, Salina D, et al. Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo. Nat Med 2012; 18: 1386-1393.
62. Yousefi S, Mihalache C, Kozlowski E, et al. Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps. Cell Death Differ 2009; 16: 1438-1444.
63. von Bruhl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209: 819-835.
64. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010; 107: 15880-15885.
65. Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice. Blood 2011; 118: 3708-3714.
66. Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010; 16: 887-896.
67. Martinod K, Demers M, Fuchs TA, et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci USA 2013; 110: 8674-8679.
68. Brill A, Fuchs TA, Savchenko AS, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2012; 10: 136-144.
69. Saffarzadeh M, Juenemann C, Queisser MA, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PloS one 2012; 7: e32366.
70. Fuchs TA, Kremer Hovinga JA, Schatzberg D, et al. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood 2012; 120: 1157-1164.
71. Diaz JA, Fuchs TA, Jackson TO, et al. Plasma DNA is Elevated in Patients with Deep Vein Thrombosis. J Vasc Surg Ven Lymph Dis 2013; 1:341-348.
72. van Montfoort ML, Stephan F, Lauw MN, et al. Circulating nucleosomes and neutrophil activation as risk factors for deep vein thrombosis. Arterioscler Thromb Vasc Biol 2013; 33: 147-151.
73. de Boer OJ, Li X, Teeling P, et al. Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction. Thromb Haemost 2013; 109: 290-297.